Sculptra (Injectable Poly-L-Lactic Acid)

Sanjay P. Keni, Douglas M. Sidle*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


As contemporary antiviral therapy provides patients who have HIV effective long-term management of their disease, the prevalence of HIV-associated lipoatrophy is increasing. Sculptra (injectable poly-L-lactic acid) is FDA approved for the treatment of HIV-associated lipoatrophy and has been shown to increase skin thickness for up to 2 years. The number of treatment sessions depends on the volume of deficiency to be treated. As is true for any cosmetic treatment, expectations must be carefully managed, especially considering the common need for multiple Sculptra treatments.

Original languageEnglish (US)
Pages (from-to)91-97
Number of pages7
JournalFacial plastic surgery clinics of North America
Issue number1
StatePublished - Feb 1 2007

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Sculptra (Injectable Poly-L-Lactic Acid)'. Together they form a unique fingerprint.

Cite this